The abstract is read at the publisher; the summary is JClub's.
Non-cysteine covalent inhibitors targeting lysine, serine, tyrosine, threonine, and histidine are increasingly explored to expand covalent drug discovery beyond cysteine dominance.
- Why it matters: Cysteine has historically limited covalent chemistry, so broadening to other residues addresses the need for new warheads, selectivity strategies, and ways to map and evaluate these modifications in therapeutic settings.
- What they did: The review surveys current warhead chemistries, selectivity approaches, proteomic mapping advances, and methods to assess intrinsic electrophile reactivity for irreversible targeting of non-cysteine residues.
- The result: It outlines key challenges and future directions, highlighting how non-cysteine covalent modifications could expand the druggable proteome and inform pharmacological implications in therapy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.